Publications by authors named "N Koen van Riessen"

F magnetic resonance imaging (F MRI) is an emerging technique for quantitative imaging in novel therapies, such as cellular therapies and theranostic nanocarriers. Nanocarriers loaded with liquid perfluorocarbon (PFC) typically have a (single) core-shell structure with PFC in the core due to the poor miscibility of PFC with organic and inorganic solvents. Paramagnetic relaxation enhancement acts only at a distance of a few angstroms.

View Article and Find Full Text PDF
Article Synopsis
  • Increased levels of the anti-inflammatory peptide Catestatin (CST) are linked to milder symptoms in conditions like hypertension, colitis, and diabetes.
  • CST inhibits the movement of immune cells (monocytes and macrophages) toward inflammatory signals, particularly CCL2 and CXCL2.
  • This research indicates that CST's ability to regulate immune cell migration contributes to its anti-inflammatory effects.
View Article and Find Full Text PDF

The exponential growth of research on cell-based therapy is in major need of reliable and sensitive tracking of a small number of therapeutic cells to improve our understanding of the in vivo cell-targeting properties. In-labeled poly(lactic--glycolic acid) with a primary amine endcap nanoparticles ([In]In-PLGA-NH NPs) were previously used for cell labeling and in vivo tracking, using SPECT/CT imaging. However, to detect a low number of cells, a higher sensitivity of PET is preferred.

View Article and Find Full Text PDF

With the advent of novel immunotherapies, interest in ex vivo autologous cell labeling for in vivo cell tracking has revived. However, current clinically available labeling strategies have several drawbacks, such as release of radiolabel over time and cytotoxicity. Poly(lactic--glycolic acid) nanoparticles (PLGA NPs) are clinically used biodegradable carriers of contrast agents, with high loading capacity for multimodal imaging agents.

View Article and Find Full Text PDF
Article Synopsis
  • Tumor-specific neoantigens are effective but hard to identify and manufacture personalized vaccines, while tumor-associated antigens offer a more accessible "off the shelf" solution.
  • A PLGA-based nanoparticle vaccine was developed, combining the immunogenic NY-ESO-1 antigen with IMM60, which activates iNKT cells and boosts dendritic cell function.
  • The vaccine demonstrated a strong immune response with minimal toxicity, showcasing its potential for production under GMP standards and ability to induce targeted T cell responses.
View Article and Find Full Text PDF